Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Clofazimine does not lead to significant QT interval prolongation: a multicentre study

Sanne M.H. Zweijpfenning, Hester van Groningen, Jakko van Ingen, Cecile Magis-Escurra, Martin J. Boeree, Dirk Wagner, Hannelore Bax, Claire Andrejak, Reinier Wener, Ananna Rahman, Heinke Kunst, Natalie Lorent, Marc A. Brouwer, Wouter Hoefsloot on behalf of NTM-NET
European Respiratory Journal 2018 52: 1801386; DOI: 10.1183/13993003.01386-2018
Sanne M.H. Zweijpfenning
1Dept of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hester van Groningen
1Dept of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jakko van Ingen
2Dept of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jakko van Ingen
Cecile Magis-Escurra
1Dept of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin J. Boeree
1Dept of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk Wagner
3Dept of Infectious Diseases, University Medical Center Freiburg, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannelore Bax
4Dept of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Andrejak
5Dept of Pulmonary Diseases, Centre Hospitalier Universitaire Amiens, Amiens, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reinier Wener
6Dept of Pulmonary Diseases, Utrecht University Medical Center, Utrecht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ananna Rahman
7Dept of Respiratory Medicine, Bart's Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heinke Kunst
8Queen Mary University of London, Barts and The London School of Medicine and Dentistry, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalie Lorent
9Dept of Pulmonary Diseases, University Hospitals Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc A. Brouwer
10Dept of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wouter Hoefsloot
1Dept of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wouter Hoefsloot
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Clofazimine does not lead to significant QT interval prolongation in the treatment of nontuberculous mycobacteria http://ow.ly/sXC330lIbI8

To the Editor:

We read with great interest the article by Pontali et al. [1], entitled “Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence”. In response to this paper and the debate on potential QTc prolongation in clofazimine- and bedaquiline-containing multidrug-resistant tuberculosis (MDR-TB) treatment regimens [2, 3], we assessed QTc prolongation during clofazimine use in treatment of disease caused by nontuberculous mycobacteria (NTM). This is important as NTM disease treatment typically includes multiple potential QTc-prolonging antibiotics, including macrolides, fluoroquinolones and, increasingly, clofazimine [4].

In a mixed prospective and retrospective study promoted through the NTM-NET (NTM Network European Trials Group) website (www.ntm-net.org; study #7), we measured QTc intervals in patients on clofazimine-based regimens for NTM disease. We only enrolled patients who had at least one ECG at the start of therapy (or in the 3 weeks before or after the start) and one ECG after at least 3 months of clofazimine use, to ensure steady state was reached [5]. Patients with pre-existing QTc prolongation and those simultaneously using bedaquiline were excluded from the study.

Enrolment of eligible patients was started in October 2012 and continued until September 2017. We applied American Heart Association standards and the Bazett formula to calculate QTc. Severe QTc prolongation, necessitating interruption of drugs, was defined as a QTc interval ≥500 ms [6]. Electrolyte measurements were available for some of the patients.

We enrolled 18 patients (11 prospective, seven retrospective): 10 (56%) men and eight women, with a mean age of 49.7±21.1 years and a mean QTc at baseline of 404.4±28.2 ms. 15 patients had pulmonary NTM disease, three patients had extrapulmonary disease; causative species are presented in figure 1a. All patients were treated with at least two QTc-prolonging antimycobacterial drugs (clofazimine and macrolide). 13 (72%) patients used at least one (up to five) other potentially QTc-prolonging drugs, e.g. proton pump inhibitors in nine patients and anti-emetics in six. 33% of the patients had one follow-up ECG, 28% had two follow-up ECGs, 17% had three follow-up ECGs and 22% had five or more follow-up ECGs. The last available follow-up ECG was made after a mean of 213.2±168.1 days after start of clofazimine therapy.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

a) Causative nontuberculous mycobacteria species for the 18 patients included in this study. M. tilburgii: Mycobacterium tilburgii; MAC: untypeable Mycobacterium avium complex; M. intracellulare: Mycobacterium intracellulare; M. abscessus: Mycobacterium abscessus; M. chimaera: Mycobacterium chimaera; M. avium: Mycobacterium avium. b) Maximum change in QTc from baseline during follow-up, per patient. c) QTc intervals measured during follow-up. Patient 17 was treated twice, hence the labels 17.1 and 17.2.

For Mycobacterium avium complex (MAC) disease (M. avium, Mycobacterium intracellulare, Mycobacterium chimaera and untypeable MAC), a clofazimine-ethambutol-macrolide regimen was given to seven (77.8%) out of the nine patients. Four of these patients also used a rifamycin and amikacin. Two patients had a clofazimine-rifamycin-macrolide regimen. The core treatment regimen for six Mycobacterium abscessus patients consisted of clofazimine-macrolide-amikacin-imipenem (or cefoxitin); four received additional tigecycline. One patient, with Mycobacterium tilburgii disease, had a clofazimine-macrolide-rifabutin-protionamide regimen.

In our cohort, the administration of clofazimine did not lead to significant QTc prolongation. The maximum change in QTc between baseline and follow-up ECG was a mean of 39.2±24.5 ms (figure 1b), which falls within the changes of 50–65 ms considered normal variation by circadian rhythm [6]. All QTc interval lengths measured during treatment are shown in figure 1c. The patterns of intra-patient fluctuation also suggest this may be mere circadian rhythm. One patient developed a QTc interval of 501 ms after 6 weeks of clofazimine-macrolide-amikacin-tigecycline-imipenem treatment for NTM disease, with concomitant itraconazole and ondansetron which can cause QTc prolongation. After treatment cessation and re-introduction of antimycobacterial drugs, but not azoles and ondansetron, this patient no longer showed QTc interval prolongation.

Studies in tuberculosis patients receiving bedaquiline and clofazimine have hinted at clofazimine as a cause of QTc prolongation [2]. Two recent studies have addressed the safety of clofazimine-based treatment regimens for NTM disease, including some QTc interval data. In one study, 40 patients had ECGs but none showed QTc intervals ≥500 ms (highest 473 ms) [7]. The second study included 35 patients using clofazimine for MDR-TB or NTM disease; one patient had to stop clofazimine-moxifloxacin-macrolide treatment because of QTc interval prolongation (550 ms) and one patient experienced cardiac arrest in the absence of QTc interval prolongation (445 ms) [8]. Furthermore, in a study in tuberculosis patients, clofazimine use was safe, but a trend towards more frequent deaths was observed in this group [9]. Such findings could not be replicated in our smaller study.

QTc interval prolongation observed with clofazimine and bedaquiline use could have been primarily due to bedaquiline use, or specifically to the bedaquiline-clofazimine combination [2, 3, 10]. This warrants future prospective studies, as this combination is likely to gain importance in mycobacterial disease treatment [5].

The main limitation of our study is the fact that follow-up was not standardised, due to its observational character. Whether QTc prolongation is dependent on clofazimine's slow accumulation in tissues is not known [5]. Long-term follow-up with frequent ECGs in larger cohorts is needed to settle this issue. Also, we applied a definition of >500 ms as QTc prolongation, although the US Food and Drug Administration guide for industry suggests that drug-induced increases >60 ms (observed in three of our patients) should be regarded as QTc prolongation [6].

In summary, clofazimine did not cause significant QTc interval prolongation in this small cohort of patients treated for NTM disease. In patients with an increasing QTc interval, this could not be related specifically to clofazimine use; concomitant medication should also be used with caution. Critical review of QTc-prolonging drugs and follow-up of electrolyte levels and ECGs are still advised in patients starting clofazimine-based NTM disease treatment.

Footnotes

  • Conflict of interest: S.M.H. Zweijpfenning reports grants and non-financial support for a clinical trial from Novartis and Insmed, outside the submitted work.

  • Conflict of interest: H. van Groningen has nothing to disclose.

  • Conflict of interest: J. van Ingen has nothing to disclose.

  • Conflict of interest: C. Magis-Escurra has nothing to disclose.

  • Conflict of interest: M.J. Boeree has nothing to disclose.

  • Conflict of interest: D. Wagner has nothing to disclose.

  • Conflict of interest: H. Bax nothing to disclose.

  • Conflict of interest: C. Andrejak has nothing to disclose.

  • Conflict of interest: R. Wener has nothing to disclose.

  • Conflict of interest: A. Rahman has nothing to disclose.

  • Conflict of interest: H. Kunst has nothing to disclose.

  • Conflict of interest: N. Lorent has nothing to disclose.

  • Conflict of interest: M.A. Brouwer has nothing to disclose.

  • Conflict of interest: W. Hoefsloot reports grants from Insmed Corp, during the conduct of the study.

  • Received April 4, 2018.
  • Accepted August 22, 2018.
  • Copyright ©ERS 2018

References

  1. ↵
    1. Pontali E,
    2. Sotgiu G,
    3. Tiberi S, et al.
    Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J 2017; 50: 1701462.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Wallis RS
    . Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J 2016; 48: 1526–1527.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Tadolini M,
    2. Lingtsang RD,
    3. Tiberi S, et al.
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. Eur Respir J 2016; 48: 1527–1529.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. van Ingen J,
    2. Ferro BE,
    3. Hoefsloot W, et al.
    Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence. Expert Rev Anti Infect Ther 2013; 11: 1065–1077.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Cholo MC,
    2. Mothiba MT,
    3. Fourie B, et al.
    Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. J Antimicrob Chemother 2017; 72: 338–353.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Rautaharju PM,
    2. Surawicz B,
    3. Gettes LS, et al.
    AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram. Part IV: the ST segment, T and U waves, and the QT interval. A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009; 53: 982–991.
    OpenUrlFREE Full Text
  7. ↵
    1. Martiniano SL,
    2. Wagner BD,
    3. Levin A, et al.
    Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection. Chest 2017; 152: 800–809.
    OpenUrl
  8. ↵
    1. Yoon HY,
    2. Jo KW,
    3. Nam GB, et al.
    Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. Int J Tuberc Lung Dis 2017; 21: 996–1001.
    OpenUrl
  9. ↵
    1. Dalcolmo M,
    2. Gayoso R,
    3. Sotgiu G, et al.
    Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. Eur Respir J 2017; 49: 1602445.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Dannemann B,
    2. Bakare N,
    3. De Marez T, et al.
    QTcF prolongation in a phase II trial of TMC207 plus background regimen as treatment for multidrug-resistant tuberculosis: effect of co-administration with clofazimine. Presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA; September 9–12, 2012. Poster A-1259.
PreviousNext
Back to top
View this article with LENS
Vol 52 Issue 5 Table of Contents
European Respiratory Journal: 52 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clofazimine does not lead to significant QT interval prolongation: a multicentre study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Clofazimine does not lead to significant QT interval prolongation: a multicentre study
Sanne M.H. Zweijpfenning, Hester van Groningen, Jakko van Ingen, Cecile Magis-Escurra, Martin J. Boeree, Dirk Wagner, Hannelore Bax, Claire Andrejak, Reinier Wener, Ananna Rahman, Heinke Kunst, Natalie Lorent, Marc A. Brouwer, Wouter Hoefsloot
European Respiratory Journal Nov 2018, 52 (5) 1801386; DOI: 10.1183/13993003.01386-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Clofazimine does not lead to significant QT interval prolongation: a multicentre study
Sanne M.H. Zweijpfenning, Hester van Groningen, Jakko van Ingen, Cecile Magis-Escurra, Martin J. Boeree, Dirk Wagner, Hannelore Bax, Claire Andrejak, Reinier Wener, Ananna Rahman, Heinke Kunst, Natalie Lorent, Marc A. Brouwer, Wouter Hoefsloot
European Respiratory Journal Nov 2018, 52 (5) 1801386; DOI: 10.1183/13993003.01386-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Correspondence

  • Reply to questions about FEV1Q and bronchodilator responsiveness
  • FEV1Q: it may be useful, but is it helpful?
  • Improving pulmonary function test interpretation
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society